Aromatase inhibitors are the class of medication that decreases estrogen synthesis in peripheral tissues. These drugs block an enzyme called aromatase, which converts androgens (hormones produced by the adrenal glands) into estrogen in tissues like fat, bone, breast, skin, and brain. In postmenopausal women, where the ovaries have stopped producing estrogen, these peripheral tissues become the body’s primary estrogen source, making aromatase inhibitors highly effective at suppressing estrogen levels throughout the body.
How Aromatase Inhibitors Work
Aromatase is the rate-limiting enzyme in estrogen production. It takes androgens and converts them into estrogen, a process that happens not just in the ovaries but in fat cells, bone, liver, muscle, brain tissue, and breast tissue. In premenopausal women, the ovaries dominate estrogen production. But after menopause, fat tissue becomes the major source of circulating estrogen, and aromatase is what makes that conversion possible.
Aromatase inhibitors shut down this conversion. In clinical studies using highly sensitive measurement methods, letrozole drove estrogen levels below detectable thresholds in 89 out of 90 postmenopausal breast cancer patients. Both major forms of circulating estrogen were completely suppressed during treatment. This near-total suppression is what makes these drugs so effective for conditions that depend on estrogen to grow.
Three FDA-Approved Options
Three aromatase inhibitors are widely used today, and they fall into two categories based on how they interact with the enzyme.
Nonsteroidal (Type II) inhibitors bind reversibly to aromatase, blocking it as long as the drug is present in the body:
- Anastrozole (brand name Arimidex)
- Letrozole (brand name Femara), which has a half-life of about 42 hours, meaning it stays active in the body for roughly two days per dose
Steroidal (Type I) inhibitors bind permanently to aromatase, destroying the enzyme molecule even after the drug itself clears from circulation:
- Exemestane (brand name Aromasin)
The practical difference: if you stop taking a nonsteroidal inhibitor, aromatase function can resume relatively quickly. With exemestane, the body has to produce entirely new aromatase enzymes before estrogen synthesis restarts. All three are taken as daily oral tablets.
What These Medications Treat
The primary use is hormone receptor-positive breast cancer in postmenopausal women. Because many breast cancers rely on estrogen to fuel their growth, cutting off peripheral estrogen production can slow or stop tumor progression. Aromatase inhibitors are used both after surgery to reduce recurrence risk and in advanced disease to control tumor growth.
Beyond breast cancer, these medications have found a role in several other conditions. Letrozole is considered first-line therapy for ovulation induction in women with polycystic ovary syndrome (PCOS) who have a BMI over 30, outperforming the older standard medication clomiphene citrate in live birth rates. Aromatase inhibitors are also used in combination with other hormonal therapies to manage endometriosis-related pain, since endometrial tissue growth is driven by estrogen.
Bone Loss Is the Major Side Effect
Because estrogen plays a critical role in maintaining bone density, suppressing it with aromatase inhibitors accelerates bone loss. This is the most significant side effect and the one that requires the most active monitoring.
Postmenopausal women on aromatase inhibitors lose bone at an estimated rate of 2.6% per year, substantially faster than the natural bone loss that occurs after menopause. In one large trial, women taking anastrozole for five years had an 11% fracture rate, significantly higher than the comparison group. Letrozole showed similar patterns: after two years, total hip bone density dropped 3.6% compared to less than 1% with placebo.
The risk is even more pronounced in premenopausal women who take aromatase inhibitors alongside medications that suppress ovarian function. In that group, bone loss rates reach approximately 7% per year. One trial found lumbar spine bone density dropped 17.4% over three years in premenopausal women receiving both an aromatase inhibitor and ovarian suppression.
A 10% to 15% decrease in bone density roughly doubles fracture risk. Fractures occur at all skeletal sites except the hip, and this elevated risk persists even after accounting for age, weight, and time since menopause. Bone density monitoring with regular scans is standard practice during treatment, and many patients take bone-protective medications alongside their aromatase inhibitor.
Joint Pain and Other Effects
Joint stiffness and pain, sometimes called aromatase inhibitor-associated musculoskeletal symptoms, affect a large proportion of patients. The discomfort typically shows up in the hands, wrists, knees, and feet, and it can be significant enough that some patients switch to a different aromatase inhibitor or discontinue treatment. Hot flashes, fatigue, and mood changes also occur, reflecting the body’s adjustment to very low estrogen levels. These side effects overlap considerably with menopausal symptoms, which makes sense given that the mechanism is the same: estrogen deprivation.
Why They Only Work in Certain Patients
Aromatase inhibitors are not effective as standalone therapy in premenopausal women. The reason is straightforward: the ovaries produce far more estrogen than peripheral tissues do, and aromatase inhibitors cannot suppress ovarian production. When estrogen levels drop from peripheral blockade, the body’s feedback system simply signals the ovaries to produce more. In premenopausal women who need aromatase inhibitor therapy for breast cancer, the ovaries must first be suppressed with additional medication or surgery.
In postmenopausal women, the ovaries are no longer active, so peripheral tissues are the only remaining estrogen source. Blocking aromatase in fat, bone, and breast tissue effectively eliminates nearly all circulating estrogen. This is why these medications achieve such dramatic suppression in postmenopausal patients, driving estrogen to undetectable levels in most cases.